39.72
Grail Inc Aktie (GRAL) Neueste Nachrichten
What drives GRAIL LLC stock priceHigh-yield trading alerts - Autocar Professional
What analysts say about GRAIL LLC stockMarket-crushing profits - jammulinksnews.com
GRAIL LLC Stock Analysis and ForecastBreakthrough financial growth - jammulinksnews.com
Freenome's new CEO is ready to compete in race for tests that can detect cancer earlySan Francisco Business Times - The Business Journals
(GRAL) Technical Data - news.stocktradersdaily.com
Is GRAIL LLC a good long term investmentGame-changing returns - jammulinksnews.com
Grail posts latest trial data for Galleri cancer detection test - MSN
Grail’s CFO Freidin sells $311k in common stock - Investing.com India
Grail’s CFO Freidin sells $311k in common stock By Investing.com - Investing.com Nigeria
Grail (GRAL) PT Hiked to $38 at Morgan Stanley amid ‘Equal Weight’ Stance - MSN
GRAIL’s Galleri Multi-Cancer Test Shows Strong Performance in PATHFINDER 2 Study, Paves Way for FDA Submission - MSN
12 Best Young Stocks To Buy and Hold For 5 Years - Insider Monkey
Illumina: A Compelling Buy Despite GRAIL Divestiture and Macroeconomic Challenges - AInvest
Illumina: Higher Profit Margin Despite GRAIL Divestiture And Macroeconomic Headwinds - Seeking Alpha
Grail (GRAL): A High-Reward, High-Risk Play on Cancer Detection's Future - AInvest
15 Successful Spin-Off Companies and Their 2025 Returns - Insider Monkey
GRAIL Insiders Selling US$10m In Stock Relieved As Market Cap Slides To US$1.7b - simplywall.st
GRAIL's Insider Sales: Red Flag or Strategic Move? Assessing Executive Confidence Amid Strong Financials - AInvest
(GRAL) Trading Report - news.stocktradersdaily.com
GRAIL, Inc.(NasdaqGS: GRAL) added to Russell 2500 Value Index - MarketScreener
GRAIL, Inc.(NasdaqGS: GRAL) dropped from Russell Midcap Index - MarketScreener
Galleri Early Detection Test May Improve Cancer Detection vs SOC Alone - CancerNetwork
Institutional investors in GRAIL, Inc. (NASDAQ:GRAL) lost 9.3% last week but have reaped the benefits of longer-term growth - Yahoo Finance
Grail plans FDA filing for cancer blood test after new trial - pharmaphorum
Grail reports positive outcomes from registrational study of Galleri test - Yahoo Home
Grail plans to submit updated Galleri blood test for FDA approval next year - Fierce Biotech
Grail stock gains on new data for Galleri cancer test (GRAL) - Seeking Alpha
GRAIL reports positive results from cancer detection test study By Investing.com - Investing.com Nigeria
GRAIL reports positive results from cancer detection test study - Investing.com Australia
GRAIL Announces Positive Top-Line Results From The Galleri PATHFINDER 2 Registrational Study - MarketScreener
Grail reports results from PATHFINDER 2 study - TipRanks
Revolutionary Cancer Screening Test Achieves Major Clinical Success: GRAIL's Galleri Outperforms Previous Study - Stock Titan
GRAL Stock Surges: What Drives the Excitement? - timothysykes.com
GRAIL: Too Much A Leap Of Faith (NASDAQ:GRAL) - Seeking Alpha
California State Teachers Retirement System Takes $464,000 Position in Grail, Inc. (NASDAQ:GRAL) - Defense World
67,288 Shares in Grail, Inc. (NASDAQ:GRAL) Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
NINGI short Grail, says ‘approval and commercialization all but impossible’ - TipRanks
GRAIL stock tumbles on short-seller report By Investing.com - Investing.com Nigeria
GRAIL stock tumbles on short-seller report - Investing.com
Ningi Research Says Short Grail - marketscreener.com
3 Medical Technology Stocks Outperforming in 2025 - inkl
GRALGRAIL Reports First Quarter 2025 Financial Results - mx.advfn.com
Wellington Management Group LLP Takes Position in Grail, Inc. (NASDAQ:GRAL) - Defense World
Two Sigma Advisers LP Makes New $345,000 Investment in Grail, Inc. (NASDAQ:GRAL) - Defense World
For FMCG Inc., the holy grail of volume growth is in sight | Company Business News - Mint
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):